Determining targets for antiretroviral drug concentrations: a causal framework illustrated with pediatric efavirenz data from the CHAPAS-3 trial

Determining targets for antiretroviral drug concentrations: a causal framework illustrated with pediatric efavirenz data from the CHAPAS-3 trial

<p><strong>Background: </strong>Determining a therapeutic window for maintaining antiretroviral drug concentrations within an appropriate range is required for identifying effective dosing regimens. The limits of this window are typically calculated using predictive models...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Schomaker, M, Denti, P, Bienczak, A, Burger, D, Díaz, I, Gibb, DM, Walker, AS, McIlleron, H
Format:	Journal article
Język:	English
Wydane:	Wiley 2024

Podobne zapisy

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
od: Bienczak, A, i wsp.
Wydane: (2016)

Plasma efavirenz exposure, sex, and age predict virological response in HIV-infected African children.
od: Bienczak, A, i wsp.
Wydane: (2016)

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource‐limited settings
od: Alemseged Abdissa, i wsp.
Wydane: (2014-01-01)

Pharmacokinetics of antiretroviral drugs in infancy
od: Helen McIlleron, i wsp.
Wydane: (2009-12-01)

Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets
od: Bienczak, A, i wsp.
Wydane: (2017)

Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.
od: Fillekes, Q, i wsp.
Wydane: (2011)

The effect of diurnal variation, CYP2B6 genotype, and age on the pharmacokinetics of nevirapine in African Children
od: Bienczak, A, i wsp.
Wydane: (2016)

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania
od: Selemani Saidi Sungi, i wsp.
Wydane: (2018-10-01)

Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz
od: Larru B, i wsp.
Wydane: (2014-05-01)

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
od: Mulenga, V, i wsp.
Wydane: (2016)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
od: Kekitiinwa, A, i wsp.
Wydane: (2017)

Getting drug doses right in children with tuberculosis (TB)
od: H. McIlleron
Wydane: (2014-04-01)

‘Covering the tail’ after stopping efavirenz-based antiretroviral therapy
od: Gary Maartens
Wydane: (2020-01-01)

Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
od: Musiime, V, i wsp.
Wydane: (2014)

Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy
od: Innocent Lule Segamwenge, i wsp.
Wydane: (2018-01-01)

Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy
od: Globahan Ajibola, i wsp.
Wydane: (2020-01-01)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
od: Vandercam Bernard, i wsp.
Wydane: (2010-05-01)

Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
od: Oudijk, J, i wsp.
Wydane: (2012)

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy
od: Dorward, J, i wsp.
Wydane: (2023)

A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis
od: Roeland E. Wasmann, i wsp.
Wydane: (2023-04-01)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
od: Chang Huang, i wsp.
Wydane: (2023-03-01)

Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy.
od: Jan Vesterbacka, i wsp.
Wydane: (2013-01-01)

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis
od: Richard Court, i wsp.
Wydane: (2021-04-01)

Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission.
od: Patience Nyakato, i wsp.
Wydane: (2020-01-01)

Combination of Antiretroviral Drugs Zidovudine and Efavirenz Impairs Tumor Growths in a Mouse Model of Cancer
od: Marcel A. Schneider, i wsp.
Wydane: (2021-11-01)

Efavirenz in pregnancy
od: Polly Clayden, i wsp.
Wydane: (2010-11-01)

Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
od: Lufina Tsirizani Galileya, i wsp.
Wydane: (2023-11-01)

Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis
od: Lufina Tsirizani Galileya, i wsp.
Wydane: (2023-11-01)

Estratégias utilizadas para o incremento da solubilidade do fármaco antiretroviral classe II: Efavirenz
od: Tarcyla Andrade Gomes, i wsp.
Wydane: (2015-04-01)

Estratégias utilizadas para o incremento da solubilidade do fármaco antiretroviral classe II: Efavirenz
od: Tarcyla Andrade Gomes, i wsp.
Wydane: (2015-10-01)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
od: Adelline Twimukye, i wsp.
Wydane: (2021-11-01)

Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
od: Sanjeev Sinha, i wsp.
Wydane: (2017-12-01)

Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans
od: Jenna Johnston, i wsp.
Wydane: (2019-04-01)

Efavirenz-induced urolithiasis.
od: Wirth, G, i wsp.
Wydane: (2006)

Efavirenz and neuropsychiatric effects
od: Mukesh Dheda
Wydane: (2017-04-01)

Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study
od: Sinxadi Phumla Z, i wsp.
Wydane: (2012-10-01)

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
od: Gabriella Jomara da Silva, i wsp.
Wydane: (2023-05-01)

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
od: Rebecca Zash, MD, i wsp.
Wydane: (2018-07-01)

Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil
od: T. Vanni, i wsp.
Wydane: (2007-07-01)

Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe
od: Sandra Shawarira-Bote, i wsp.
Wydane: (2019-08-01)